Summary
The Coronavirus (COVID-19) company impact report analyses how the pandemic has impact the top 20 Mega Cap Bio/Pharma Companies revenue, future revenue, and market capitalization.
Scope
Reasons to Buy
The Coronavirus (COVID-19) company impact report analyses how the pandemic has impact the top 20 Mega Cap Bio/Pharma Companies revenue, future revenue, and market capitalization.
Scope
- This report gives an important expert analysis on how COVID-19 has affected, and will continue to affect, the top 20 Mega Cap Bio/Pharma Companies. Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.
Reasons to Buy
- An overview of how the top 20 Mega Cap Bio/Pharma Companies have been affected, and will continue to be affected, by the COVID-19 pandemic.
Table of Contents
1. Market Cap Change for Bio/Pharma Companies in Q1 2020
2. Market Cap for Top 20 Bio/Pharma Companies: Q1 2020 vs. 2019
3. Drug Sales for Top 20 Bio/Pharma Companies vs. Market Cap
4. Drug Sales for Top 20 Bio/Pharma Companies Q1 2020 vs. Q4 2019
5. Drug Sales for Top 20 Bio/Pharma Companies vs. Archived Forecasts
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Merck & Co Inc
- Pfizer Inc
- Bristol-Myers Squibb Co
- Amgen Inc
- AbbVie Inc
- AstraZeneca Plc
- Eli Lilly and Co
- Sanofi
- GlaxoSmithKline Plc
- Novo Nordisk AS
- CSL Ltd
- Gilead Sciences Inc
- Bayer AG
- Allergan Plc
- Vertex Pharmaceuticals Inc
- Biogen Inc
- Regeneron Pharmaceuticals Inc
![Human Microbiome Market: Trends, Forecast and Competitive Analysis [2024-2030] - Product Image](http://www.researchandmarkets.com/product_images/12371/12371581_60px_jpg/human_microbiome_market_[20242030].jpg)
